Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents

While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.